S
SheMed
Health Tech & Medtech · London, United Kingdom · Founded 2024
Personalised GLP-1 weight management platform for women MoreLess
The women's metabolic health brand. SheMed offers the UK's first clinician-led GLP-1 medical weight loss programme and dedicated PMOS (formerly PCOS) programme, with prescribing and dispensing through CQC-registered eMed and GPhC-registered pharmacy partner eMed Healthcare UK Limited. Personalised, evidence-based care, women-focused throughout. Trusted by over 100,000 women.
In 2025, the company raised a $50 million Series A, reaching unicorn status as the second UK femtech unicorn after Flo Health. The funding supports UK operations, clinical research, and expansion of its medical and technology teams. Sister brand HeMed extends the same clinician-led model to men.
Keywords: women's health, digital health platform, GLP-1, weight management, telehealth, personalised medicine, at-home testing, femtech, test-to-treat, metabolic health, semaglutide, tirzepatide, Wegovy, Mounjaro, Foundayo, orforglipron, weight loss, health screening, virtual care, wellness tracking, medical diagnostics, Olivia Ferro, Chloe Ferro, UK healthcare, PCOS, PMOS, perimenopause, unicorn
Talent graph
SheMed's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where SheMed has talent and traffic
team presence
across markets
Market sentiment
What the market is saying about SheMed
An AI-synthesized read of the highest-engagement posts about SheMed on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See SheMed on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.